The FDA is considering changes that could reshape how vaccines move from labs to American pharmacies — the most significant proposed shift in vaccine oversight since the early 2000s. While the agency has not formally issued draft guidance, recent public comments, advisory committee discussions and internal policy memos outline a framework that is intended to streamline clinical trials, tighten manufacturing oversight and modernize postmarket safety monitoring.
Why the FDA wants a new pathway
The push stems from an internal memo written by Vinay Prasad, MD, the FDA’s chief medical and scientific officer and director of its vaccine division. Dr. Prasad said the agency conducted a review linking 10 pediatric deaths to COVID-19 vaccination — a claim that drew swift criticism from public health experts, who said the memo lacks transparency and key data.
The FDA has since expanded the review to include adults, though federal health officials emphasize that extensive scientific evidence continues to support the safety and effectiveness of COVID-19 vaccines.
Dr. Prasad argued that the current approval model, which allows vaccines to be authorized based on antibody response data for certain updates, is no longer sufficient. He wrote that the FDA should demand stronger evidence before clearance, calling existing flu vaccine updates “a catastrophe of low-quality evidence.”
The memo said debates about reforms should occur privately within FDA walls, inviting staff who disagree to submit resignations.
Longer and more comprehensive clinical trials
Under the current model, a vaccine must demonstrate safety and effectiveness through multiple trial phases and cannot advance until each phase meets predefined endpoints. Dr. Prasad’s proposal would expand those requirements, calling for larger and longer studies that measure whether a vaccine prevents illness — not just whether it produces antibodies.
Proposed changes include:
- Trials showing reductions in disease, not just antibody production
- Safety and efficacy data across all subgroups, including pregnant people
- Randomized trials for certain bacterial vaccines, including pneumococcal shots
Former FDA commissioners warn the shift will slow routine updates and restrict the nation’s ability to keep pace with evolving pathogens.
Changes to annual vaccine processes
One of the most consequential proposals targets the annual flu vaccine process. Dr. Prasad’s memo calls for raising the evidence bar for updates, requiring manufacturers to generate more robust clinical data before approval.
Under the current framework, manufacturers update strain composition each year without launching new Phase 3 trials. The system is designed to ensure doses are reviewed, authorized and distributed ahead of peak respiratory virus transmission.
Requiring full clinical-endpoint data for each update would lengthen development and review timelines. Health leaders warn the change would delay seasonal availability and narrow the window to match vaccines to circulating strains.
Public health concerns and internal dissent
Public health experts and advocacy groups say the FDA’s memo risks undermining confidence in vaccines that have undergone years of safety monitoring. They emphasize that COVID-19 infection has been shown to carry a significantly higher myocarditis risk than vaccination.
The Infectious Diseases Society of America said the FDA’s statement about vaccine-related pediatric deaths “lacks evidence and harms the public.”
Meanwhile, former FDA commissioners warned that:
- Ending immunobridging studies would impede timely updates.
- Cost and access barriers could worsen.
- Scientific dissent must remain visible, not suppressed.
They argue the FDA’s credibility depends on open evidence review and transparent deliberation and object to proposals that would limit or bypass independent advisory committees, which traditionally review evidence in public before vaccine approvals or updates.
What it could mean for providers, payers and patients
If finalized, the road map will make vaccine regulation slower but more data intensive.
For providers:
- Delays will affect seasonal supply and immunization-clinic timelines.
- More frequent reviews may change communication with patients.
For manufacturers:
- Earlier and more extensive trial requirements will raise development costs.
- Smaller developers may struggle to keep products in the pipeline.
For patients:
- Routine access — particularly for high-risk groups — may tighten.
- Public messaging will shift as process terminology becomes more complex.
Today’s predictable cadence of full licensure for new vaccines, followed by Advisory Committee on Immunization Practices recommendations and payer coverage updates, helps health systems plan seasonal immunization workloads and supply needs. Those planning structures may face significant disruption under a more conservative review model.
The bottom line
The FDA has not said when it will release draft guidance or whether the proposals will move through the public rulemaking process. It is also unclear whether the agency will bring reforms to its advisory committee for open debate, a point former commissioners say is critical for maintaining trust.
As stakeholders await formal guidance, manufacturers and providers might need to prepare for a regulatory approach that is more conservative, more complex and considerably slower than the system that guided the COVID-19 response.
The changes, if implemented, could define the next decade of U.S. vaccination policy.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.